American Head & Neck Society
Advance Program for the AHNS 2017 Meeting at COSM

ACCREDITATION STATEMENT:
The American Head & Neck Society (AHNS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for physicians. The AHNS designates this activity for a maximum of 15.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AGENDA:

Wednesday, April 26, 2017

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION</th>
<th>FACULTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 am – 8:00 am</td>
<td>Welcome</td>
<td>Jeffrey N. Myers, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anna M. Pou, MD &amp; David Goldenberg, MD</td>
</tr>
<tr>
<td>8:00 am – 9:00 am</td>
<td><strong>Panel 1: Improving Outcomes in Oral Cavity Cancer</strong></td>
<td>Session Chair: Maie St. John, MD</td>
</tr>
<tr>
<td><strong>Faculty and Titles Subject to Change</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 am – 9:00 am</td>
<td>Panel 1: Improving Outcomes in Oral Cavity Cancer</td>
<td>Session Chair: Maie St. John, MD</td>
</tr>
<tr>
<td><strong>Faculty and Titles Subject to Change</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 am – 9:00 am</td>
<td>Panel 1: Improving Outcomes in Oral Cavity Cancer</td>
<td>Session Chair: Maie St. John, MD</td>
</tr>
<tr>
<td><strong>Faculty and Titles Subject to Change</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 am - 9:45 am</td>
<td>John Conley Lecture: Strengthening the AHNS through Diversity and Global Outreach</td>
<td>Johannes J. Fagan, MD</td>
</tr>
<tr>
<td>9:45 am - 10:45 am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45 am - 11:00 am</td>
<td>Scientific Session 1: Oral Cavity</td>
<td>Moderators: Eduardo Mendez, MD &amp; Donald T. Weed, MD</td>
</tr>
<tr>
<td>10:45 am - 11:00 am</td>
<td>Scientific Session 2: Survivorship</td>
<td>Moderators: Ara A. Chalian, MD &amp; Carol Lewis, MD</td>
</tr>
<tr>
<td>11:00 am - 12:00 pm</td>
<td>Panel 2: Advanced Non-Melanoma Skin Cancer (NMSC) of the Head and Neck</td>
<td>Session Chair: Neil D. Gross, MD</td>
</tr>
<tr>
<td><strong>Faculty and Titles Subject to Change</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 pm - 1:00 pm</td>
<td>AHNS Business Meeting or Lunch on Own</td>
<td>Francisco G. Cigarroa, MD</td>
</tr>
<tr>
<td>1:00 pm - 2:00 pm</td>
<td>Keynote Lecture</td>
<td></td>
</tr>
<tr>
<td>2:00 pm - 3:00 pm</td>
<td>Panel 3: Quality and Value in Head and Neck Reconstruction: Current Trends, Evidence and Practices</td>
<td>Session Chair: Matthew Old, MD</td>
</tr>
</tbody>
</table>

LEARNING OBJECTIVES

At the conclusion of this session, participants will be able to:
- Plan in new ways for treating the neck in oral cavity cancers
- Articulate new methods of screening oral cavity lesions
- Apply new techniques in reconstruction

LEARNING OBJECTIVES

At the conclusion of this session, participants will be able to:
- Recognize the shifting epidemiology and presenting signs of advanced-stage non-melanoma skin cancer (NMSC)
- Understand important aspects of contemporary treatment of advanced-stage non-melanoma skin cancer (NMSC)
- Review the rational application of conventional and novel treatments for advanced-stage non-melanoma skin cancer (NMSC)

With the ever increasing focus on quality in health care, the goal of this panel is to discuss the trends and evidence for quality and value in head and neck reconstruction. The AHNS Reconstruction Committee has embarked and completed many multidisciplinary projects focused on a variety reconstructive...
issues defining benchmarks and increasing quality and value. The purpose of this panel is to discuss the results of these projects and review the current evidence for head and neck reconstructive practices.

- Quality and Value in Head and Neck Reconstruction: Current Trends, Evidence and Practices
  Matthew Old, MD
- Post-Operative Non-ICU Care: Value, Current Protocols, and Data
  Vasu Divi, MD
- Predictors of Complications and Readmissions and the Downstream Effects
  Derrick Lin, MD
- Functional Outcomes After Major Head and Neck Reconstruction
- Antibiotic Usage in Head and Neck Reconstruction
  Jeremy Richmon, MD
- Flap Surveillance Study/Resident Work Hours
  Tamer Ghanem, MD
  Urjeet Patel, MD

LEARNING OBJECTIVES
At the conclusion of this session, participants will be able to:
- Develop post-operative non-ICU care for free flaps based on current protocols and data
- Develop a post-operative antibiotic usage protocol in head and neck reconstruction
- Employ a post-operative flap surveillance protocol based on the current evidence presented

2:00 pm - 3:00 pm  Panel 4: Bringing Unconscious Bias into the Conscious in Head and Neck Surgery
  Session Chair: Amy Y. Chen, MD, MPH
This panel of three speakers and a moderator will describe the framework of implicit/ unconscious bias, the research of implicit bias in the workplace, and lastly, how unconscious bias impacts the field of head and neck surgery.

- Introduction
  Amy Y. Chen, MD, MPH
- Framework of Implicit Bias
  Thierry Devos, PhD
- How Does Diversity and Inclusion Enhance to Workplace
  Beth G. Chung, PhD
- Implicit Bias: Lessons Learned
  Carol R Bradford, MD
- Conclusion and Audience Q&A
  Amy Y. Chen, MD, MPH

LEARNING OBJECTIVES
At the conclusion of this session, participants will be able to:
- Describe what is unconscious bias.
- Articulate the findings from research regarding implicit bias in the workplace.
- Recognize the importance of strategies to decrease unconscious bias in head and neck surgery.

3:00 pm - 3:30 pm  Break

3:30 pm - 4:30 pm  Scientific Session 3: Thyroid & Parathyroid
  Moderators: Michael C. Singer, MD & David Steward, MD

3:30 pm - 4:30 pm  Scientific Session 4: Head & Neck Reconstruction
  Moderators: Trevor G. Hackman, MD & Jalisi Scharukh, MD

4:30 pm - 5:30 pm  Panel 5: Nuances in the Management of Parathyroid Diseases
  Session Chair: David Steward, MD
This panel of experts will discuss nuances in the management of hyperparathyroidism, including: normocalcemic hyperparathyroidism, hypercalcemia with inappropriately normal parathyroid hormone, non-localizing hyperparathyroidism, and management of recurrent or persistent hyperparathyroidism.

- Normocalcemic Hyperparathyroidism
  Michael C. Singer, MD
- Normohormonal Hyperparathyroidism
  David C. Shonka, MD
- Non-Localizing Disease
  Emad Kandil, MBCh
- Management of Persistent or Recurrent Disease
  Brendan C. Stack, MD

LEARNING OBJECTIVES
At the conclusion of this session, participants will be able to:
- Recognize the differences between normocalcemia primary hyperparathyroidism and secondary hyperparathyroidism
- Distinguish between hypercalcemia caused by primary hyperparathyroidism with normal PTH values from that caused by non-parathyroid etiology
- Explain management strategy for nonlocalized primary hyperparathyroidism requiring surgery

6:00 pm - 7:00 pm  Fellowship Information Session

7:30 pm - 9:30 pm  Past Presidents' Dinner at The SkyBox
  Invitation Only
### How to Get a “Head-(and Neck) Start” to Your Career

**Jointly Sponsored by the AHNS Young Members Ad Hoc Committee, AHNS Women’s Task Force, & AHNS Diversity Ad Hoc Committee**

The hour-long breakfast panel will include 4 brief talks from well established members of the AHNS community on the topics of Professional Advancement, Job/Contract Negotiation, Establishing Translational Relationships, and Partnering with Industry, with a Q/A session to follow. The end of the session will also allow for open discussions with panelists and members and networking.

**LEARNING OBJECTIVES**
- To provide participants with tips and pearls for career advancement
- Help navigate attendees on how to create and foster relationships with institutional and industry partners
- To help participants learn successful and productive negotiating strategies early in their career

**Moderators:** Melonie Nance, MD & Thomas J. Ow, MD

**Carole Fakhry, MD, MPH**

**Eduardo Mendez, MD**

**Amy Y. Chen, MD, MPH**

**Patrick K. Ha, MD**

---

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION</th>
<th>FACULTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am - 8:45 am</td>
<td><strong>Scientific Session 5: Larynx &amp; Hypopharynx</strong></td>
<td>Moderators: Andrew McWhorter, MD &amp; Michael L. Hinni, MD</td>
</tr>
<tr>
<td>8:00 am - 8:45 am</td>
<td><strong>Scientific Session 6: Immunotherapy &amp; Genomics</strong></td>
<td>Moderators: Joseph Califano, MD &amp; John Sunwoo, MD</td>
</tr>
<tr>
<td>8:45 am - 9:30 am</td>
<td><strong>Hayes Martin Lecture:</strong> Reconstruction: The Final Dimension in Head and Surgery</td>
<td>Mark K. Wax, MD</td>
</tr>
<tr>
<td>9:30 am - 9:45 am</td>
<td><strong>AHNS Awards</strong></td>
<td></td>
</tr>
<tr>
<td>9:45 am - 10:15 am</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>10:15 am - 11:00 am</td>
<td><strong>Presidential Address and Awards</strong></td>
<td>Jeffrey N. Myers, MD, PhD</td>
</tr>
<tr>
<td>11:00 am - 12:00 pm</td>
<td><strong>Jatin P. Shah Symposium:</strong> Aggressive Thyroid Malignancies: State of the Art Management</td>
<td>Session Chair: Gregory L. Randolph, MD</td>
</tr>
</tbody>
</table>

A renowned panel of presenters will review the latest updates in the surgical management of a range of more challenging forms of thyroid cancer including aggressive and invasive differentiated thyroid cancer, Medullary and Anaplastic thyroid cancer.

**LEARNING OBJECTIVES**
- Articulate the important preop features to identify advanced thyroid cancer in order that the surgeon is prepared optimally.
- Employ the most recent guidelines based surgical care to patients with advanced thyroid cancer.
- Integrate the multiple factors important to make key decisions such as tracheotomy in anaplastic cancer and lateral neck dissection in medullary cancer.

**Moderators:** Joseph Scharpf, MD

**David Goldenberg, MD**

**Mark Zafereo**

**Ralph P. Tufano, MD**

---

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION</th>
<th>FACULTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 pm - 1:00 pm</td>
<td><strong>Lunch with Exhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>1:00 pm - 2:00 pm</td>
<td><strong>Scientific Session 7: Value Based H&amp;N Cancer Care</strong></td>
<td>Moderators: Eric Lentsch, MD &amp; Andrew J. Nemechek, MD</td>
</tr>
<tr>
<td>1:00 pm - 2:00 pm</td>
<td><strong>Scientific Session 8: Outcomes</strong></td>
<td>Moderators: Patrick K. Ha, MD &amp; Mark Zafereo, MD</td>
</tr>
<tr>
<td>2:00 pm - 3:00 pm</td>
<td><strong>Panel 6: 8th Edition of the AJCC Staging Manual: Introduction to Major Changes</strong></td>
<td>Session Chair: William M. Lydiatt, MD</td>
</tr>
</tbody>
</table>

The 8th Edition of the AJCC Staging Manual introduces major changes in several key aspects of staging head and neck cancer of vital importance to clinicians and researchers. The Head and Neck Task Force worked closely with the UICC to make sure the changes could be a world-wide modification. There are several significant changes in the system including the use of extra nodal extension as a factor in most cancers, depth of invasion in oral cavity cancer, incorporation of skin cancer in the head and neck section since it has been dropped from the
manual for the body, and most significantly, a new staging system for p16+, HPV-associated oropharyngeal cancers. This Panel presentation will include a discussion of the rational for changes for each of the major cases, presented by the leaders of the task force in each area.

• Development of a Novel Staging System in HPV –Associated Oropharyngeal Cancers and the Unknown Primary
• Incorporation of Extranodal Extension in Head and Neck Staging
• Incorporation of Depth of Invasion in Oral Cavity T Classification
• Modification and Rationale for Incorporating Skin in Head and Neck
• Discussion and Questions

LEARNING OBJECTIVES
At the conclusion of this session, participants will be able to:
• Distinguish which patients should be staged by the HPV associated staging system and which should be staged by the HPV-non-associated.
• Employ the new T category for oral cavity cancer using depth of invasion and how depth and thickness are different.
• Interpret the different ways extranodal extension will impact the staging of patients with head and neck cancers and discriminate between the sites where this is used.

2:00 pm - 3:00 pm Panel 7: Ethics in Practice: Cancer Survivorship and Its Consequences  Session Chair: Susan D. McCammon, MD

This panel will introduce key concepts of head and neck cancer survivorship, including the recent American Cancer Society’s Head and Neck Survivorship Care Guideline, and open dialogue around best practices for providing comprehensive care for this growing patient population. The panel will discuss regulatory requirements, quality metrics, and the consequences on resource allocation, medicalization and medical decision making.

• Readiness for Survivorship Regulation and Accreditation
• Prioritizing Quality Metrics for Survivorship Programs
• Medical Decision-Making in the Era of Prolonged Survival
• Survival, Cure, Recurrence: The Effects of Upstreaming Palliative Care
• Questions

LEARNING OBJECTIVES
At the conclusion of this session, participants will be able to:
• Describe current accreditation and regulatory requirements for survivorship programs and assess their own institution’s readiness.
• Compare and prioritize current quality metrics for cancer survivorship and implement best practices for state of the science survivorship programs.
• Predict how anticipation of prolonged future survival affects present medical decision making about treatment and supportive care.

3:00 pm - 3:30 pm Break

3:30 pm - 5:00 pm Scientific Session 9: Oropharynx  Moderators: Jason G. Newman, MD & Richard Smith, MD

3:30 pm - 5:00 pm Scientific Session 10: Clinical Research  Moderators: Amy Y. Chen, MD, MPH & Larry L. Myers, MD

5:30 pm - 7:00 pm President’s Poster Discussion Session

Poster Tour Leaders:
- Clinical Research: William M. Lydiatt, MD
- Clinical Trials/NMSC/Immunotherapy: Rohan R. Walvekar, MD
- Endocrine: Maria Evasovich, MD
- Genomics/Basic Science: Young Kim, MD, PhD
- Larynx/Hypopharynx: Genevieve A. Andrews, MD
- Oral Cavity: Maie St. John, MD
- Oropharynx: William R. Ryan, MD
- Outcomes: Lana L. Jackson, MD
- Reconstruction/Robotics: Jason T. Rich, MD
- Survivorship: Susan D. McCammon, MD
- Value: Marilene B. Wang, MD

7:30 pm - 8:30 pm President’s Reception
**Industry Satellite Symposia 2017**
These presentations are planned and presented by our corporate colleagues. AHNS does not take responsibility for the content.

**Immune-Mediated Treatment in Head and Neck Cancer: Transforming Care?**
Tuesday, April 25 at 6:00 pm - 7:15 pm
5:45 pm - 6:00 pm - Registration, Dinner and Refreshments
Room: Gaslamp A-D
Presented by MEDSCAPE, LLC

Invited speakers:
- **Barbara A. Burtness, MD**  
  Professor of Medicine  
  Disease Aligned Research Team Leaders  
  Head and Neck Cancers Program  
  Co-Director  
  Developmental Therapeutics Research Program  
  Yale University School of Medicine, New Haven, Connecticut

- **Robert I. Haddad, MD**  
  Disease Center Leader  
  Head and Neck Oncology Program  
  Dana Farber Cancer Institute  
  Boston, Massachusetts

The recent approval of immune checkpoint inhibitors and the fast-paced development of emerging therapies have had a major impact on the management of head and neck cancer. This program will zero in on what clinicians need to know about these therapies, how to integrate them into practice, and what to expect in the near future.

---

**Transforming Outcomes in Head and Neck Cancer: Immunotherapy Takes Center Stage**
Wednesday, April 26 at 6:15 am
Room: Seaport ABC
Presented by prIME Oncology

This engaging symposium focuses on the contemporary management of advanced HNSCC with immunotherapy, including the rationale for targeting the immune system in HNSCC and concepts of immunotherapeutic approaches. Case-based management discussions provide considerations and guidance for the current use of immune checkpoint inhibition in the management of recurrent and metastatic HNSCC, including patient selection, potential biomarkers, evaluation of response, and treatment of unique immune-related adverse events. Approaches for how emerging immunotherapy strategies may be used in multidisciplinary care of HNSCC, along with patient video snippets, provide important information for practice application.

Invited Speakers:
- **Chair – Ezra Cohen, MD**  
  University of California at San Diego  
  San Diego, California, United States

- **Robert Haddad, MD**  
  Dana-Farber Cancer Institute  
  Boston, Massachusetts, United States

- **Andrew Sikora, MD, PhD**  
  Baylor College of Medicine  
  Houston, Texas, United States